BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19184558)

  • 1. An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma.
    Nakamura M; Miki Y; Akahira J; Morimoto R; Satoh F; Ishidoya S; Arai Y; Suzuki T; Hayashi Y; Sasano H
    Endocr Pathol; 2009; 20(1):17-23. PubMed ID: 19184558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
    Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
    Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathologic features and expression of epidermal growth factor receptor and vascular endothelial growth factor in adrenocortical tumors].
    Wang CP; Zhang J; Gao J; Liu PP; Wu SF; Zeng X; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):686-90. PubMed ID: 23302311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status.
    Zhang J; Wang C; Gao J; Sun J; Zeng X; Wu S; Liang Z
    Diagn Pathol; 2014 Jan; 9():19. PubMed ID: 24457059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?
    Bulzico D; Faria PAS; Maia CB; de Paula MP; Torres DC; Ferreira GM; Pires BRB; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
    Endocrine; 2017 Nov; 58(2):276-288. PubMed ID: 28887601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome.
    Adam P; Hahner S; Hartmann M; Heinrich B; Quinkler M; Willenberg HS; Saeger W; Sbiera S; Schmull S; Voelker HU; Ströbel P; Allolio B; Fassnacht M
    Mod Pathol; 2010 Dec; 23(12):1596-604. PubMed ID: 20693985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
    Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential.
    Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M
    Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma.
    Poli G; Ceni E; Armignacco R; Ercolino T; Canu L; Baroni G; Nesi G; Galli A; Mannelli M; Luconi M
    Oncotarget; 2015 Mar; 6(8):5695-706. PubMed ID: 25691058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma.
    Romero Arenas MA; Whitsett TG; Aronova A; Henderson SA; LoBello J; Habra MA; Grubbs EG; Lee JE; Sircar K; Zarnegar R; Scognamiglio T; Fahey TJ; Perrier ND; Demeure MJ
    Ann Surg Oncol; 2018 Mar; 25(3):801-807. PubMed ID: 29218429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
    De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma.
    Poli G; Ruggiero C; Cantini G; Canu L; Baroni G; Armignacco R; Jouinot A; Santi R; Ercolino T; Ragazzon B; Assie G; Mannelli M; Nesi G; Lalli E; Luconi M
    J Clin Endocrinol Metab; 2019 May; 104(5):1712-1724. PubMed ID: 30476173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
    Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients.
    Chabre O; Libé R; Assie G; Barreau O; Bertherat J; Bertagna X; Feige JJ; Cherradi N
    Endocr Relat Cancer; 2013 Aug; 20(4):579-94. PubMed ID: 23756429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
    Kiiveri S; Liu J; Arola J; Heikkilä P; Kuulasmaa T; Lehtonen E; Voutilainen R; Heikinheimo M
    Mol Cell Endocrinol; 2005 Apr; 233(1-2):47-56. PubMed ID: 15767045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.
    Sbiera I; Kircher S; Altieri B; Lenz K; Hantel C; Fassnacht M; Sbiera S; Kroiss M
    Front Endocrinol (Lausanne); 2021; 12():795116. PubMed ID: 34956100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen-related receptor α in normal adrenal cortex and adrenocortical tumors: involvement in development and oncogenesis.
    Felizola SJ; Nakamura Y; Hui XG; Satoh F; Morimoto R; M McNamara K; Midorikawa S; Suzuki S; Rainey WE; Sasano H
    Mol Cell Endocrinol; 2013 Jan; 365(2):207-11. PubMed ID: 23123734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.